Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RS_001
- Development stage
- Preclinical
- Lead developer
- Redesign Science
- Modality
- Small Molecules
01
Overview
RS_001 is a preclinical small molecule Targeted Protein Interaction Modulator (TPIM™) being developed by Redesign Science for the treatment of mild to moderate inflammatory bowel disease (IBD). Discovered using the company's proprietary NUVO™ technology platform—which integrates physics-based molecular dynamics with machine learning—RS_001 is designed to target and modulate protein-protein interactions mediated by specific localization domains. By influencing the spatial distribution and functional activity of key proteins involved in the inflammatory cascade, RS_001 aims to provide a novel therapeutic approach for IBD patients. As of early 2024, the program is in the lead optimization stage of development.
Beyond the preview
Go deeper on RS_001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RS_001.